Intralesional injection of lauromacrogol in mucoceles: An efficacy controlled clinical trial.

Abstract

Mucoceles represent one of the common benign diseases of the oral mucosa. Resection is the conventional therapeutic approach for mucoceles; however, micro-marsupialization and sclerotherapy are employed to achieve minimum invasion. According to previous reports, one of the sclerosants used is lauromacrogol. Our study aimed to assess the safety and short-as well as long-term efficacy of intralesional injection of 1% lauromacrogol in treating mucoceles. 392 patients were enrolled and divided into two groups: the local injection group (LI group) and the surgical removal group (SR group). Measurements were conducted at the 1st, 3rd, 6th, and 12th months. Clinical parameters prior to group allocation included the maximal diameter of the lesion; the characteristics documented after treatment included subjective pain level, presence of swelling, and occurrence of numbness. With cure rates of 91.33% and 92.35%, respectively, there was little difference between the SR and LI groups. The recurrence rates were modest in both groups. Notably, in the LI group but not in the SR group, the variables of gender and the initial maximum diameter showed a significant correlation with recurrence. Additionally, in both groups, lesion location, treatment history, and patient age did not significantly correlate with recurrence of the lesion.